Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
Amy S. Ruppert, Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Steven Coutré, Jennifer R. Brown, Sreenivasa Nattam, Richard A. Larson, Harry P. Erba, Mark R. Litzow, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Scott E. Smith, Richard M. Stone, John C. Byrd, Sumithra J. Mandrekar, Jennifer A. Woyach
Topics & Concepts
IbrutinibBendamustineMedicineInternal medicineAdverse effectRituximabCumulative incidenceGastroenterologyChronic lymphocytic leukemiaLymphomaLeukemiaCohortChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentGastrointestinal Tumor Research and Treatment